Phase II Study of Adjuvant SIB Radiotherapy Following Narrow-Margin Hepatectomy in Patients With HCC.

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 26, 2024

Primary Completion Date

December 12, 2025

Study Completion Date

December 12, 2026

Conditions
Hepatocellular CarcinomaNarrow MarginRadiotherapy
Interventions
RADIATION

Adjuvant SIB radiotherapy

Eligibility patients will receive IMRT or VMAT to high risk area of tumor bed and tumor bed. The prescription dose to 95% GTVtb boost was planned at 55-60Gy, with PTV 45-50Gy, in 23-25 fractions,mainly depending on the dose constraints of OARs.

Trial Locations (1)

Unknown

RECRUITING

Bo Chen, Beijing

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER